Ocugens COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81% – GlobeNewswire

By:
On:
In: ENTERTAINMENT
With: 0 Comments
  • Data from 25,800 participants in Phase 3 trial in India, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated and demonstrated 81% efficacy in preve… [+9774 chars]
    Post Views: 21

Leave a Reply

Your email address will not be published. Required fields are marked *